|
The person heading this unique
company is Dr.Krishna Ella,a Ph.D.
from The University of Wisconsin,
Madison and a M.S.,from The
University of Hawaii. Dr.Krishna
Ella has also won a lot of Academic
Awards such as the National Research
Service Award, Rotary Foundation
(Chicago, Illinois) Fellowship,
Indian Council of Agri. Research
Fellow, University Gold medallist
for highest C.G.P.A.,American Spring
(ASPEE) Gold Medallist and also
bagged the Rotary International
prize.
He has also been honoured with the
'Dr. K.C. Chatterjee Memorial Award'
from the Indian Pharamaceutical
Association, India in 1999.Had been
the Member, National Task Force,
Industrial Biotechnology in 1999.He
was also the :Vice-President, All
India Biotech Association,
India(1999-2000).He is the Member-
Pharma Task Force, Govt. of A.P
About Bharat Biotech
International Limited:
Bharat Biotech International
Limited, Hyderabad, India has taken
up the challenge of providing
premier health care products to the
common man.The company taken the
route of Genetic Engineering and
Biotechnology to achieve our goal of
ensuring a healthy tomorrow.
Established in the year 1996, the
company is a torch bearer in the
field of developing Next-Generation
Vaccines and Biopharmaceuticals
through original and collaborative
research.
Its pioneering and incessant
research led to the launch of Revac-B,
the immensely effective Recombinant
Vaccine for Hepatitis-B, the killer
disease, in 1998.
Its the world's second largest
Hepatits B manufacturing plant with
a capacity 100 million doses per
annum, conforming to USFDA, UK-MCA &
WHO standards.
Its major Product is REVAC - B which
is Second-generation genetically
engineered vaccine developed in
recombinant strains of yeast,
indicated for vaccination against
Hepatitis B.The Worlds first Cesium
Chloride free (CsCl) Vaccine
manufactured using the patented
innovative in-house production
process - HIMAX Technology. Contains
highly purified HbsAg conforming to
pharmacopoeia standards.Over 30
million doses dispensed.
Bharat Biotech has also became the
first Biotechnology company in the
country and second of its kind in
the world to manufacture and market
Recombinant Streptokinase the
primary drug for dissolving blood
clots, a common occurrence during a
heart attack. The Drug Controller
General of India, the national
regulatory authority for Indian
pharmacopoeia, granted the
commercial licence to BBIL on
Thursday, August 14, 2003.
The company has bagged the National
Award For Promotion of Biotechnology
in the area of Medical
Biotechnology- Vaccines and also
bagged the National Award For Best R
& D Efforts In Industry.
|
